COSENSE-1 is an unblinded, phase II, single-armed, single center feasibility study for using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens, for male and female participants aged 18 and older, with microsatellite stable (MSS)/proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC), that is incurable or not resectable with curative intent.
Age 18 or older
ECOG performance status 0 or 1
Obtained informed consent
Acceptable organ function (defined in publicly available protocol)
Patient has metastatic MMR deficient/MSI adenocarcinoma
Patient is ineligible for full (100%) chemotherapy doses at first treatment cycle
Patient is not equally eligible for FOLFOX (+/- antibody) and FOLFIRI (+/- antibody) chemotherapy regimens, according to the Norwegian national guideline on the treatment of colorectal cancer
ECOG performance status 2 or worse
St. Olavs Hospital
Lead sponsor
Norwegian University of Science and Technology
Collaborator